Current Impact and Application of Abuse-Deterrent Opioid Formulations in Clinical Practice

被引:1
|
作者
Lee, Ya-Han [1 ]
Brown, Daniel L. [2 ]
Chen, Hsiang-Yin [1 ,3 ]
机构
[1] Taipei Med Univ, Sch Pharm, Dept Clin Pharm, 250 Wu Hsin St, Taipei, Taiwan
[2] Calif Hlth Sci Univ, Coll Pharm, Clovis, CA USA
[3] Taipei Med Univ, Wan Fang Hosp, Dept Pharm, Taipei, Taiwan
关键词
Opioid abuse; abuse-deterrent formulations; ADF; post-marketing; FDA guidance; cost impact; abuse liking; physician attitude; generic abuse-deterrent formulation; clinical application; TAMPER-RESISTANT FORMULATIONS; EXTENDED-RELEASE HYDROCODONE; UNITED-STATES; CHRONIC PAIN; DOUBLE-BLIND; POSTOPERATIVE PAIN; SUBSTANCE-ABUSE; RISK-EVALUATION; NONMEDICAL USE; SINGLE-ENTITY;
D O I
暂无
中图分类号
R614 [麻醉学];
学科分类号
100217 ;
摘要
Background: Abuse-deterrent formulations (ADFs) represent one novel strategy for curbing the potential of opioid abuse. Objective: We aim to compare and contrast the characteristics and applications of current abuse-deterrent opioid products in clinical practice. Methods: Literature searches were conducted in databases (Pubmed Medline, International Pharmaceutical Abstracts, Google Scholar) and official reports. Relevant data were screened and organized into: 1) epidemiology of opioid abuse, 2) mitigation strategies for reducing opioid abuse, 3) development of ADFs, and 4) clinical experience with these formulations. Results: Increasing trends of opioid abuse and misuse have been reported globally. There are 5 types of abuse-deterrent opioid products: physical chemical barrier, combined agonist/antagonist, sequestered aversive agent, prodrug, and novel delivery system. The advantages and disadvantages of the 5 options are discussed in this review. A total of 9 products with abuse-deterrent labels have been approved by the Food and Drug Administration (FDA). The rates of abuse, diversion, and overdose deaths of these new products are also discussed. A framework for collecting in-time data on the efficacy, benefit and risk ratio, and cost-effectiveness of these new products is suggested to facilitate their optimal use. Limitations: The present review did not utilize systematic review standards or meta-analytic techniques, given the large heterogeneity of data and outcomes reviewed. Conclusions: ADFs provide an option for inhibiting the abuse or misuse of oral opioid products by hindering extraction of the active ingredient, preventing alternative routes of administration, or causing aversion. Their relatively high costs, uncertain insurance policies, and limited data on pharmacoeconomics warrant collaborative monitoring and assessment by government agencies, pharmaceutical manufacturers, and data analysis services to define their therapeutic role in the future.
引用
收藏
页码:E1003 / E1023
页数:21
相关论文
共 50 条
  • [31] Abuse-Deterrent Formulations, an Evolving Technology Against the Abuse and Misuse of Opioid Analgesics
    Schaeffer, Tammi
    JOURNAL OF MEDICAL TOXICOLOGY, 2012, 8 (04) : 400 - 407
  • [32] ABUSE-DETERRENT FORMULATIONS OF OPIOIDS: EFFECTIVENESS AND ECONOMIC IMPACT
    Agboola, F. O.
    Kumar, V. M.
    Synnott, P. G.
    Chapman, R. H.
    Banken, R.
    Ollendorf, D. A.
    VALUE IN HEALTH, 2018, 21 : S191 - S191
  • [33] Impact of abuse-deterrent OxyContin on prescription opioid utilization
    Hwang, Catherine S.
    Chang, Hsien-Yen
    Alexander, G. Caleb
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2015, 24 (02) : 197 - 204
  • [34] Current and future development of extended-release, abuse-deterrent opioid formulations in the United States
    Webster, Lynn R.
    Markman, John
    Cone, Edward J.
    Niebler, Gwendolyn
    POSTGRADUATE MEDICINE, 2017, 129 (01) : 102 - 110
  • [35] Challenges Involved in the Development and Delivery of Abuse-deterrent Formulations of Opioid Analgesics
    Cohen, Joshua P.
    Mendoza, Mario
    Roland, Carl
    CLINICAL THERAPEUTICS, 2018, 40 (02) : 334 - 344
  • [36] Abuse-Deterrent Formulations of Prescription Opioids
    Ruan, Xiulu
    Chiravuri, Srinivas
    Kaye, Alan D.
    JAMA PSYCHIATRY, 2015, 72 (08) : 849 - 850
  • [37] Current approaches in tamper-resistant and abuse-deterrent formulations
    Mastropietro, David J.
    Omidian, Hossein
    DRUG DEVELOPMENT AND INDUSTRIAL PHARMACY, 2013, 39 (05) : 611 - 624
  • [38] Reducing risk with abuse-deterrent formulations
    Thomas, Felicity
    1600, UBM Medica Periodical Publication (44): : 24 - 27
  • [39] Abuse-Deterrent Opioid Formulations Part of a Public Health Strategy to Reverse the Opioid Epidemic
    Kunins, Hillary V.
    JAMA INTERNAL MEDICINE, 2015, 175 (06) : 987 - 988
  • [40] Abuse-Deterrent and Tamper-Resistant Opioid Formulations What is their Role in Addressing Prescription Opioid Abuse?
    Schneider, Jennifer P.
    Matthews, Michele
    Jamison, Robert N.
    CNS DRUGS, 2010, 24 (10) : 805 - 810